Sprache auswählen
Integrin alpha V beta 6
Integrin alpha V beta 6 Molekülinformation
| Englischer Name | Integrin alpha-V/beta-6 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 | Target-Alias | |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Integrin alpha-V/beta-6 |
| Target-Alias | |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
Integrin alpha V beta 6 Produktliste
- Attribut
Protein (8)Cell (2)Kits (1)
- Produktbibliothek
Online (11)
- Spezies
Human (5)Mouse (2)Cynomolgus (2)Rat (1)Mouse & Human (1)
- Etikett
His Tag (5)His Tag & Avi Tag (3)- (3)
- Marker
Unconjugated (5)Biotin-labeled (3)- (3)
In den Warenkorb legen
Gesamtmenge11
- 1
- 2
Integrin alpha V beta 6 Molekülhintergrund
Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Idiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Bexotegrast | PLN-74809 | Phase 2 Clinical | Pliant Therapeutics Inc | Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult | Details |
| Nesvategrast | SF-0166; OTT-166(OcuTerra Therapeutics) | Phase 2 Clinical | OcuTerra Therapeutics Inc, Scifluor Life Sciences Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
| 18F-αvβ6-Binding-Peptide | 18F-αvβ6-BP | Phase 1 Clinical | National Cancer Institute, National Institutes Of Health | Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Lung Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| [18F]FP-R01-MG | [18F]FP-R01-MG-F2; [18F]FP-R01-MG | Phase 1 Clinical | Chinese Academy Of Medical Science & Peking Union Medical College, Pliant Therapeutics Inc, Stanford University | Brain metastases; Carcinoma, Non-Small-Cell Lung; Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Pancreatic Neoplasms | Details |
| Ga-68-Trivehexin | RAD-301 | Phase 1 Clinical | Trimt GmbH | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | Details |
Produktrezensionen
A***l2022-03-15
0Menschen mögenGreat communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!
- Molekülinformation
- Produktliste
- Produktrezensionen
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main